entertainment -WSS

entertainment

author：comprehensive 2025-08-12 06:42:18 - browse：546

Stock exchange — Drew Angerer/Getty Images

Structure Therapeutics reported Monday that its oral GLP-1 drug led to weight loss in two small studies, leading shares to surge in pre-market trading.

In a 12-week Phase 2a study, the daily pill in a capsule formulation led to 6.2% placebo-adjusted weight loss. In a separate 12-week pharmacokinetics study, the company tested a new tablet formulation of the drug, called GSBR-1290, and it led to placebo-adjusted weight loss of up to 6.9%.

Though it’s difficult to compare across different studies, the results appear to approach the levels of weight loss seen at 12 weeks in a separate Phase 2 study of Eli Lilly’s GLP-1 pill called orforglipron. That entire study lasted 36 weeks, but at 12 weeks, participants had about 6%-7% placebo-adjusted weight loss.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Live blog: Hearing on CRISPR

hotspot

WSS

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

Breakthrough Alzheimer’s drugs are inaccessible in rural states

Explaining an after

Medicare proceeds with plan to claw back hospital funds

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Wikipedia

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Anesthesiologist group: stop taking Ozempic before surgery

Vertex non

Sports medicine is finally prioritizing gender equality

Gene therapy’s promise and the high cost of hope

Tori Bowie and the unacceptable rates of Black maternal death

‘Oppenheimer’ and the risks of AI in health care

Guidelines to prevent youth baseball injuries need more muscle

Micronoma's microbiome cancer diagnostic approach under fire

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

DeepMind touts AlphaFold's new skills as protein folding AI models face off

entertainment

Infectious disease expert Jeanne Marrazzo assumes Fauci role

Travis Kelce and the trap of celebrity vaccine endorsements

All of Us, NIH's precision medicine initiative, gets a big boost

Micronoma's microbiome cancer diagnostic approach under fire

After Sarepta trial failure, Duchenne families brace for more debate

National panel will explore requiring free Covid tests

leisure time

hotspot

hotspot

focus